BiotechTube
Polaris Genomics

Polaris Genomics

Rockville, United States· Est.
polarisgenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Polaris Genomics is a privately held, veteran-founded diagnostics company established in 2015, headquartered in Rockville, Maryland. The company's core offering is the ADAPT Neuropsychiatric Biomarker Discovery Platform™, a research tool that analyzes genetic and transcriptomic data to identify RNA expression profiles correlated with conditions like PTSD, depression, and anxiety. Polaris is translating this platform into clinical diagnostics, beginning with PTS-ID™, a first-of-its-kind blood test for PTSD screening and triage. The company targets partnerships with pharmaceutical, academic, and clinical research organizations to advance biomarker-driven drug development and clinical tools.

PsychiatryNeuroscience

Technology Platform

The ADAPT Neuropsychiatric Biomarker Discovery Platform™: A targeted neuropsychiatric gene panel combined with a deep analytics engine and data repository. It analyzes genetic association, transcriptomic (RNA expression), and clinical phenotypic data from liquid biopsy (blood) samples to identify biomarker signatures for neuropsychiatric conditions using machine learning.

Opportunities

The massive, underserved mental health market lacks objective diagnostic tools, creating a prime opportunity for first-movers like Polaris.
The company's veteran focus provides a clear initial market pathway and potential for non-dilutive government funding.
Its platform model allows for expansion into multiple high-prevalence conditions (depression, anxiety) and lucrative partnerships with pharmaceutical companies for biomarker-driven drug development.

Risk Factors

Key risks include the scientific challenge of validating robust biomarkers for complex neuropsychiatric conditions and the commercial difficulty of changing clinical practice and securing insurance reimbursement.
The company also faces competition from other entities developing mental health diagnostics and the risk that alternative biomarker modalities may gain traction.

Competitive Landscape

Polaris operates in an emerging but competitive space. It faces competition from other startups focused on genomic or other biomarker-based mental health tests, large clinical labs developing LDTs, and academic consortia. Its differentiation lies in its integrated platform, veteran-focused initial product, and explicit mission to apply an oncology-like biomarker strategy to psychiatry.

More companies in United States →